<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162174</url>
  </required_header>
  <id_info>
    <org_study_id>200816212-1</org_study_id>
    <nct_id>NCT01162174</nct_id>
  </id_info>
  <brief_title>Pilot Study of Oligonol Supplementation to Promote Cardiovascular Health</brief_title>
  <official_title>Effects of Oligonol on Vascular Function and Inflammation in Healthy Men: A Double-Blind, Dose-Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amino Up Chemical Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that acute consumption of Oligonol, a patented lychee fruit&#xD;
      extract (Amino Up Chemical Co.) particularly rich in low molecular weight flavanols, will&#xD;
      improve endothelial function, reduce platelet reactivity and increase circulating levels of&#xD;
      flavonoids after a single intake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have demonstrated from previous studies at UC Davis that a single dose of a&#xD;
      high-flavanol supplement from cocoa can improve endothelial function, measured by increased&#xD;
      blood flow from peripheral arterial tonometry (PAT), reduce platelet reactivity, and increase&#xD;
      circulating levels of flavonoids in the blood. The investigators seek with this proposal to&#xD;
      determine if a similar response can be noted with a different high-flavanol supplement in&#xD;
      normal, healthy people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral Arterial Tonometry</measure>
    <time_frame>0 and 2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cardiovascular Health</condition>
  <arm_group>
    <arm_group_label>100 mg of Oligonol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg of Oligonol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0 mg of Oligonol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oligonol</intervention_name>
    <arm_group_label>0 mg of Oligonol</arm_group_label>
    <arm_group_label>100 mg of Oligonol</arm_group_label>
    <arm_group_label>200 mg of Oligonol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-50 yrs.&#xD;
&#xD;
          -  Healthy, not taking prescription medications&#xD;
&#xD;
          -  Subject is willing and able to comply with the study protocols.&#xD;
&#xD;
          -  Subject is willing to consume the Oligonol extract drink or placebo once a week for&#xD;
             each of three weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Physical signs of health impairment.&#xD;
&#xD;
          -  Abnormal clinical laboratory (CBC, chemistry, liver, etc.) values if determined to be&#xD;
             clinically significant by Dr. Eric Gershwin&#xD;
&#xD;
          -  Inflammatory disorders (e.g. rheumatoid arthritis)&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  Treatment with corticosteroids, hypolipidemic and anti-inflammatory drugs&#xD;
&#xD;
          -  Renal or Liver disease&#xD;
&#xD;
          -  Heart Disease, which includes cardiovascular events and stroke&#xD;
&#xD;
          -  Cushing's syndrome&#xD;
&#xD;
          -  History of psychiatric disorders i.e. schizophrenia or bi-polar or depression treated&#xD;
             with antidepressants within the last 1 year.&#xD;
&#xD;
          -  Anti-anxiety medications&#xD;
&#xD;
          -  Routine use of prescription drugs or over-the counter medications, which may&#xD;
             potentially modulate the outcome of this study; including antibiotics, aspirin and&#xD;
             aspirin-containing formulations, COX-2 inhibitors, antihistamines, corticosteroids,&#xD;
             ACE-inhibitors, and beta-blockers, erectile dysfunction drugs.&#xD;
&#xD;
          -  Asthma (can be worsened by mild to moderate food allergies).&#xD;
&#xD;
          -  Indications of substance or alcohol abuse within the last 3 years&#xD;
&#xD;
          -  Undergoing nicotine cessation therapy&#xD;
&#xD;
          -  Multi-Vitamin and mineral use other than a One-A-Day type formula&#xD;
&#xD;
          -  Current, consistent use of herbal or plant-based supplements; omega-3 fatty acids, and&#xD;
             fish or unwilling to discontinue use while participating in the study.&#xD;
&#xD;
          -  Alcohol consumption &gt; 1 oz/day (2 beers/day or 2 glasses of wine/ day, 1 drink of hard&#xD;
             liquor/day)&#xD;
&#xD;
          -  Chronic high-intensity exercise&#xD;
&#xD;
          -  Smoking&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Hackman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>July 13, 2010</last_update_submitted>
  <last_update_submitted_qc>July 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Carl L Keen</name_title>
    <organization>University of California, Davis</organization>
  </responsible_party>
  <keyword>Flavanols</keyword>
  <keyword>cardiovascular</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

